首页 Ligand Pharmaceuticals(usLGND)-基本信息

Ligand Pharmaceuticals(usLGND)-基本信息

日报更新时间:

周报更新时间:04-11 03:39

行情信息

今开价:152.76

最高价:153.67

成交量:169779.0

昨收价:153.44

最低价:144.81

最新价:144.9

行情图标
概要信息

英文名称:Ligand Pharmaceuticals


行业:医疗


简介:Ligand Pharmaceuticals Incorporated于1987年在特拉华州注册,是一家生物制药公司


电话:1-858-5507500


最新量化综合结论
百科信息
  • 相关网站
  • 员工交易记录
  • 持股信息
  • 领导人信息

交易日期 交易人 职位 类型 交易份额 价格
2019-08-04 Aryeh (Jason M) Director Buy 746 90.01
2019-08-04 Berkman (Charles S) General Counsel Buy 424 85.79
2019-08-04 Berkman (Charles S) General Counsel Buy 669 56.26
2019-08-01 Patel (Sunil) Director Buy 1000 95.98
2019-08-01 Davis (Todd Clifton) Director Buy 1000 93.59
2019-07-31 LaMattina (John L) Director Buy 2500 32.30
2019-07-31 LaMattina (John L) Director Sell 847 95.58
2019-07-30 Higgins (John L) Chief Executive Officer Buy 1850 95.45
2019-07-30 Aryeh (Jason M) Director Buy 754 93.00
2019-07-30 Sabba (Stephen L. M.D.) Director Sell 4091 94.45
2019-07-29 Aryeh (Jason M) Director Buy 3000 100.22
2019-07-28 Aryeh (Jason M) Director Buy 250 106.01
2019-06-27 Berkman (Charles S) General Counsel Buy 182 97.03
2019-06-27 Korenberg (Matthew E) Chief Financial Officer Buy 182 97.03
2019-06-10 Aryeh (Jason M) Director Buy 250 107.01
2019-06-10 Foehr (Matthew W) President Buy 1004 21.92
2019-06-05 Gray (Nancy Ryan) Director Buy 835 --
2019-06-05 Patel (Sunil) Director Buy 835 --
2019-06-05 Aryeh (Jason M) Director Buy 835 --
2019-06-05 LaMattina (John L) Director Buy 835 --
2019-06-05 Sabba (Stephen L. M.D.) Director Buy 835 --
2019-06-05 Davis (Todd Clifton) Director Buy 835 --
2019-06-05 Kozarich (John W.) Director Buy 835 --
2019-05-30 Higgins (John L) Chief Executive Officer Buy 1000 108.20
2019-05-30 Aryeh (Jason M) Director Buy 500 108.51

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Goldman Sachs Group Inc 376340 1.92% 75692 25.18% 2019-03-31
William Blair Investment Management, LLC 887642 4.53% -89642 -9.17% 2019-03-31
Janus Capital Management LLC 1114971 5.69% 156110 16.28% 2019-07-31
State Street Corporation 1290508 6.58% 285574 28.42% 2019-03-31
HHG PLC 1385066 7.07% 396166 40.06% 2019-03-31
Renaissance Technologies Corp 1415708 7.22% -65111 -4.40% 2019-03-31
Vanguard Group Inc 1932196 9.86% 2346 0.12% 2019-03-31
BlackRock Fund Advisors 1937699 9.89% -2344352 -54.75% 2019-07-31
BlackRock Inc 2739255 13.98% -22606 -0.82% 2019-03-31
Cardinal Capital Management Llc 882515 4.50% 376043 74.25% 2019-03-31
SSGA Funds Management Inc 733847 3.74% 334 0.05% 2019-07-31
Conestoga Capital Advisors, LLC 621006 3.17% 134173 27.56% 2019-03-31
Manufacturers Life Insurance Co 557512 2.84% 152649 37.70% 2019-03-31
Vanguard Investments Australia Ltd 520414 2.66% -41125 -7.32% 2019-07-31
Northern Trust Investments Inc 494951 2.53% -8455 -1.68% 2019-07-31
Macquarie Group Ltd 490782 2.50% 51195 11.65% 2019-03-31
Thrivent Financial For Lutherans 426721 2.18% 147537 52.85% 2019-03-31
Stephens Inv Mgmt Group LLC 425644 2.17% 17299 4.24% 2019-03-31
Delaware Management Company 417799 2.13% -59585 -12.48% 2019-07-31
Invesco Capital Management LLC 409343 2.09% -31189 -7.08% 2019-07-31
Victory Capital Management Inc. 469600 2.40% 31475 7.18% 2018-12-31
Ameriprise Financial Inc 685998 3.50% 41686 6.47% 2018-12-31
Geode Capital Management, LLC 496920 2.54% 269229 118.24% 2018-12-31
BlackRock Asset Management Canada Ltd 2846645 14.52% -279 -0.01% 2019-05-31
Wells Fargo & Co 408733 2.08% 140520 52.39% 2018-12-31
Millennium Management LLC 546957 2.78% 450791 468.76% 2018-12-31
Eagle Asset Management, Inc. 443276 2.25% 40527 10.06% 2018-12-31
OppenheimerFunds Inc 443412 2.25% 74326 20.14% 2018-12-31
Bank of New York Mellon Corp 407336 1.99% -90892 -18.24% 2018-12-31
Amvescap Plc. 442556 2.08% 147169 49.82% 2018-09-30
Fidelity Management and Research Company 536331 2.52% 95747 21.73% 2018-09-30
FMR Inc 536632 2.52% 96048 21.80% 2018-09-30
Fidelity Management & Research Company 414973 1.95% -4550 -1.08% 2018-11-30
Columbia Mgmt Investment Advisers, LLC 408728 1.92% 44 0.01% 2018-06-30
BlackRock Institutional Trust Company NA 647871 3.05% 8664 1.36% 2018-06-30
State Street Corp 910727 4.32% -39562 -4.16% 2018-06-30
Knott David M 553041 2.60% -209903 -27.51% 2018-03-31
Columbia Mangmt Investment Advisers, LLC 408728 1.94% 44 0.01% 2018-06-30
Delaware Management Business Trust 397113 1.88% 9970 2.58% 2018-06-30
William Blair Investment Mgmt 307164 1.46% -29946 -8.88% 2018-07-31
Columbia Wanger Asset Management LLC 314001 1.49% -30976 -8.98% 2018-07-31
Glenmede Trust Co NA 392932 1.53% -- -- 2018-03-31
ARONSON+JOHNSON+ORTIZ 316696 1.49% 201235 174.29% 2018-03-31
Northern Trust Investments N A 309186 1.45% -2398 -0.77% 2018-03-31
Deutsche Bank AG 373246 1.76% -14808 -3.82% 2017-12-31
Merrill Lynch & Co Inc 410889 1.94% 1856 0.45% 2017-12-31
Oak Ridge Investments, LLC 321072 1.52% -115636 -26.48% 2017-12-31
Columbia Management Company 451241 2.14% -32351 -6.69% 2017-09-30
Macquarie Investment Management Limited 463035 2.20% 463035 -- 2017-09-30
Wells Capital Management Inc. 890173 4.26% 141292 18.87% 2016-09-30
T. Rowe Price Associates, Inc. 524217 2.51% 18029 3.56% 2016-09-30
Invesco PowerShares Capital Mgmt LLC 480998 2.30% 24885 5.46% 2016-09-30
Granahan Investment Management Inc.. 305424 1.46% -19400 -5.97% 2016-09-30
Cardinal Capital Management, LLC 985795 2.00% 55973440 -- 1999-11-30
The Vanguard Group 997254 2.00% 56624082 -- 1999-11-30
Blair William &Co/IL 1165039 2.00% 66150914 0.10% 1999-11-30
David M. Knott 1318993 2.00% 74892423 0.10% 1999-11-30
BlackRock, Inc. 2025768 2.00% 115023107 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Nasdaq Biotechnology ETF 193466 0.99% 2073 1.08% 2019-07-30
Delaware Small Cap Core Fund 374940 1.91% 10425 2.86% 2019-06-30
Delaware Sm-Cap Core Eq-UBS 374940 1.91% 28155 8.12% 2019-06-30
iShares Russell 2000 ETF 421221 2.15% 5177 1.24% 2019-07-30
Conestoga Small Cap 424450 2.17% 7275 1.74% 2019-05-31
Vanguard Small Cap Index 450299 2.30% -76283 -14.49% 2019-06-30
Vanguard Total Stock Market Index Fund 515846 2.63% -41099 -7.38% 2019-06-30
iShares Core S&P Mid-Cap ETF 572350 2.92% 1100 0.19% 2019-07-30
Janus Henderson Triton Fund 849011 4.33% 124761 17.23% 2019-06-30
iShares S&P Small-Cap 600 Growth ETF 357176 1.82% -1044 -0.29% 2018-11-02
Vanguard Extended Market Index Fund 267043 1.36% -15348 -5.44% 2019-06-30
William Blair Small-Mid Cap Growth Fund 208886 1.07% 2400 1.16% 2019-06-30
SPDR 223166 1.14% -11540 -4.92% 2019-06-30
Carillon Eagle Small Cap Growth Fund 224422 1.15% -- -- 2019-06-30
T. Rowe Price QM US Small-Cap Gr Eq Fd 234800 1.20% -- -- 2019-06-30
Vanguard Explorer Fund 244702 1.25% 10141 4.32% 2019-03-31
Janus Henderson Venture Fund 255681 1.30% 31349 13.97% 2019-06-30
Vanguard Small Cap Growth Index Fund 258434 1.32% -40626 -13.58% 2019-06-30
Invesco S&P SmallCap Health Care ETF 264931 1.35% 1464 0.56% 2018-11-05
iShares Core MSCI AllCntry Wld exCan ETF 599173 3.06% -- -- 2019-05-23
iShares S&P US Mid-Cap ETF (CAD-Hedged) 598941 3.06% -- -- 2019-05-30
iShares S&P US Mid-Cap ETF 598941 3.06% -- -- 2019-05-30
iShares Core S&P US Total Market ETF 598941 3.06% -- -- 2019-05-30
iShares US Small Cap ETF (CAD-Hedged) 424875 2.17% -711 -0.17% 2019-05-30
Vanguard Small Cap Index Fund 527648 2.69% 3752 0.72% 2019-04-30
Fidelity 233398 1.19% -12500 -5.08% 2019-03-31
Columbia Acorn Fund 402109 1.97% 75444 23.10% 2019-02-28
Glenmede Small Cap Equity Portfolio 258953 1.27% 98330 61.22% 2018-12-31
Oppenheimer Discovery Fund 230100 1.13% -49180 -17.61% 2019-01-31
iShares Russell 2000 Growth ETF 189629 0.89% -384 -0.20% 2018-12-31
iShares S&P Mid-Cap 400 Growth ETF 183792 0.86% -- -- 2018-11-21
Vanguard Tax Managed Small Cap Fund 181162 0.86% -- -- 2018-10-31
Vanguard Small Cap Growth Index Inv 290809 1.38% 4358 1.52% 2018-07-31
Vanguard Explorer Inv 192530 0.91% -- -- 2018-06-30
T. Rowe Price QM US Small-Cap Growth Eq 196500 0.93% 17900 10.02% 2018-06-30
Oppenheimer Discovery A 189960 0.90% 14520 8.28% 2018-07-31
Delaware Small Cap Core A 212900 1.01% -3200 -1.48% 2018-07-31
Vanguard Total Stock Mkt Idx 515571 2.44% 506 0.10% 2018-07-31
iShares S&P Small-Cap 600 Growth 372599 1.74% 4725 1.28% 2018-09-12
Conestoga Small Cap Investors 364625 1.73% 7300 2.04% 2018-07-31
Janus Triton D 359172 1.70% -- -- 2018-06-30
PowerShares S&P SmallCap Health Care ETF 269874 1.26% 5652 2.14% 2018-09-13
Glenmede Small Cap Equity Adv 316384 1.50% 2035 0.65% 2018-06-30
iShares Nasdaq Biotechnology 242054 1.13% -462 -0.19% 2018-09-12
Eagle Small Cap Growth A 224422 1.06% -- -- 2018-06-30
William Blair Small-Mid Cap Gr I 236118 1.12% -31900 -11.90% 2018-07-31
iShares Russell 2000 Growth 202337 0.95% -195 -0.10% 2018-09-12
Columbia Acorn Z 247433 1.17% -29733 -10.73% 2018-07-31
Vanguard Extended Market Idx Inv 282161 1.34% 3800 1.37% 2018-07-31
Vanguard Tax-Managed Small Cap Adm 177662 0.84% 5800 3.37% 2018-07-31
William Blair Small-Mid Cap Growth Collective Investment Fund 161062 0.76% -- -- 2018-06-30
Pax World Small Cap Institutional 174520 0.82% -1000 -0.57% 2018-03-31
Janus Venture D 199651 0.94% -27535 -12.12% 2017-12-31
JNL Multi-Manager Small Cap Growth B 175600 0.83% 19641 12.59% 2017-09-30
Oak Ridge Small Cap Growth A 200000 0.95% -155000 -43.66% 2017-08-31
PowerShares Dynamic Pharmaceuticals ETF 344208 1.67% -- -- 2017-02-08
RS Small Cap Growth A 288055 1.38% 18192 6.74% 2016-09-30
Wells Fargo Discovery Admin 213933 1.02% -9400 -4.21% 2016-12-31
RS Select Growth A 173110 0.83% 28190 19.45% 2016-09-30
Wells Fargo Emerging Growth Admin 164271 0.79% 3544 2.20% 2016-12-31
PowerShares Dynamic Pharmaceuticals Port 726716 4.10% -- -- 2015-11-19
Oak Ridge Small Cap Growth Fund 603366 3.00% 273266 82.80% 2015-08-31
iShares Core S&P Small-Cap (AU) 467967 2.70% 632 0.10% 2015-11-19
RS Small Cap Growth Fund 342290 1.70% 22180 6.90% 2015-09-30
RS Select Growth Fund 318680 1.60% 85910 36.90% 2015-09-30
iShares Russell 2000 (AU) 277995 1.60% -348 -0.10% 2015-11-19
SPDR® S&P Biotech ETF 250136 1.40% 1624 0.60% 2015-11-19
William Blair Small-Mid Cap Growth 236701 1.20% -27558 -10.40% 2015-10-31
JNL Multi-Manager Small Cap Value Fund 207608 1.00% 207608 -- 2015-09-30
Fidelity® Select Biotechnology Portfolio 927337 4.70% -- -- 2015-09-30

John W. Kozarich Dr. John W. Kozarich is a Chairman at Intec Pharma Ltd., an Independent Director at Retrophin, Inc., a Chairman at Ligand Pharmaceuticals, Inc. and a Chief Scientific Officer & Director at ActivX Biosciences, Inc. He is on the Board of Directors at Retrophin, Inc., ActivX Biosciences, Inc., Adaptive Therapeutics, Inc., Curza Global, LLC and Gordon Research Conferences. Dr. Kozarich was previously employed as an Independent Director by QLT, Inc., an Independent Non-Executive Director by Corium International, Inc., a Vice President by Merck Research Laboratories, a Vice President-Research & Development by Alkermes, Inc., a Professor by University of Maryland, and a Professor by Yale School of Medicine. He also served on the board at Novelion Therapeutics, Inc. He received his undergraduate degree from Boston College and a doctorate degree from Massachusetts Institute of Technology.
Matthew W. Foehr Mr. Matthew W. Foehr is an Independent Director at Ritter Pharmaceuticals, Inc. and a President & Chief Operating Officer at Ligand Pharmaceuticals, Inc. He is on the Board of Directors at Ritter Pharmaceuticals, Inc. and Viking Therapeutics, Inc. Mr. Foehr was previously employed as a Chief Scientific Officer-Dermatology & VP by GlaxoSmithKline LLC, a Senior VP-Global Research & Development Operations by Stiefel Research Institute, Inc., and a Senior Vice President-Technical Operations by Connetics Corp. He received his undergraduate degree from Santa Clara University.
Charles S. Berkman Charles S. Berkman occupies the position of Secretary, Senior Vice President & General Counsel for Ligand Pharmaceuticals, Inc. and Secretary & Vice President at Metabasis Therapeutics, Inc. (a subsidiary of Ligand Pharmaceuticals, Inc.). In the past Charles S. Berkman was Attorney at Baker & McKenzie LLP (Illinois) and Attorney at Lyon & Lyon, Inc. He received an undergraduate degree from The University of Texas and a graduate degree from The University of Texas School of Law.
John L. Higgins Currently, John L. Higgins is Chairman at CoMentis, Inc. and Chief Executive Officer & Director at Ligand Pharmaceuticals, Inc. Mr. Higgins is also on the board of Bio-Techne Corp. and Blue Zones LLC. In the past Mr. Higgins was CFO & EVP-Administration & Corporate Development at Connetics Corp. and Member-Healthcare Banking Team at Dillon, Read & Co., Inc. Mr. Higgins received an undergraduate degree from Colgate University.
Eric Vajda Eric Vajda is Vice President-Preclinical Research & Development at Ligand Pharmaceuticals, Inc. Dr. Vajda received an undergraduate degree from Yale University and a doctorate from the University of Utah.
John L. LaMattina Currently, John L. LaMattina is Chairman for Gelesis, Inc. He is also on the board of 7 other companies. Dr. LaMattina previously occupied the position of President-Pfizer Global R&D at Pfizer Central Research, Director at Decision Options LLC and Senior Vice President at Pfizer Inc. and President for Pfizer Global Research & Development (a subsidiary of Pfizer Inc.). Dr. LaMattina received an undergraduate degree from Boston College and a doctorate from the University of New Hampshire.
Stephen L. Sabba Presently, Stephen L. Sabba is Analyst at Knott Partners LP. Dr. Sabba is also on the board of Ligand Pharmaceuticals, Inc. and Novelion Therapeutics, Inc. Dr. Sabba previously held the position of Research Director at Sturza Institutional Research, Director-Research at Kilkenny Capital Management LLC and Member of Kilkenny Capital Management LLC. He received an undergraduate degree from Cornell University and a doctorate from New York University School of Medicine.
Jason M. Aryeh Mr. Jason M. Aryeh is Chairman at QLT, Inc., Independent Director at Ligand Pharmaceuticals, Inc., Founder & Managing General Partner at JALAA Equities LP and a Member at Omicron Delta Epsilon. He is on the Board of Directors at Cystic Fibrosis Foundation Therapeutics, Inc., CorMatrix Cardiovascular, Inc., Ligand Pharmaceuticals, Inc. and Aralez Pharmaceuticals, Inc. He founded JALAA Equities in 1997. Mr. Aryeh served as a Director of both Nabi Biopharmaceuticals and of Myrexis, Inc., both of which were public biotechnology companies. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University.
Todd C. Davis Mr. Todd C. Davis is Founder at Healthcare Royalty Management LLC, Chairman at Helomics Corp. and Chairman at Suneva Medical, Inc. He is on the Board of Directors at Ligand Pharmaceuticals, Inc. Mr. Davis was previously employed as a Managing Director by Cowen Group, Inc. /Old/, Partner by Paul Capital Partners LP, Partner by Apax Partners, Inc., a Principal by Abbott Laboratories, and a Principal by Elan Pharmaceuticals, Inc. He also served on the board at Artes Medical, Inc., Nuron Biotech, Inc. and Verus Pharmaceuticals, Inc. He received his undergraduate degree from United States Naval Academy and an MBA from Harvard University.
Audrey Warfield-Graham Currently, Audrey Warfield-Graham holds the position of Vice President-Human Resources of Ligand Pharmaceuticals, Inc.
Matthew W. Foehr Mr. Matthew W. Foehr is an Independent Director at Ritter Pharmaceuticals, Inc. and a President & Chief Operating Officer at Ligand Pharmaceuticals, Inc. He is on the Board of Directors at Ritter Pharmaceuticals, Inc. and Viking Therapeutics, Inc. Mr. Foehr was previously employed as a Chief Scientific Officer-Dermatology & VP by GlaxoSmithKline LLC, a Senior VP-Global Research & Development Operations by Stiefel Research Institute, Inc., and a Senior Vice President-Technical Operations by Connetics Corp. He received his undergraduate degree from Santa Clara University.
Sunil Patel Sunil Patel is on the board of Ligand Pharmaceuticals, Inc. In his past career he held the position of Principal at Gilead Sciences, Inc., Principal at McKinsey & Co., Inc., CFO, Executive VP-Corporate Development & Finance at OncoMed Pharmaceuticals, Inc., Principal at Connetics Corp., Principal at Abgenix, Inc., Vice President-Corporate Development for Allos Therapeutics, Inc., Researcher at ZymoGenetics, Inc., Researcher at ProCyte Corp. and Vice President-Corporate Development & Marketing at BiPar Sciences, Inc. Mr. Patel received an undergraduate degree from the University of California, Berkeley and a graduate degree from the University of Washington.
Matthew W. Foehr Presently, Matthew W. Foehr holds the position of President & Chief Operating Officer at Ligand Pharmaceuticals, Inc. He is also on the board of Ritter Pharmaceuticals, Inc. and Viking Therapeutics, Inc. Mr. Foehr previously was Senior VP-Global Research & Development Operations at Stiefel Research Institute, Inc., Chief Scientific Officer-Dermatology & VP at GlaxoSmithKline LLC and Senior Vice President-Technical Operations at Connetics Corp. He received an undergraduate degree from Santa Clara University.
Matthew W. Foehr Mr. Matthew W. Foehr is an Independent Director at Ritter Pharmaceuticals, Inc. and a President & Chief Operating Officer at Ligand Pharmaceuticals, Inc. He is on the Board of Directors at Ritter Pharmaceuticals, Inc. and Viking Therapeutics, Inc. Mr. Foehr was previously employed as a Chief Scientific Officer-Dermatology & VP by GlaxoSmithKline LLC, a Senior VP-Global Research & Development Operations by Stiefel Research Institute, Inc., and a Senior Vice President-Technical Operations by Connetics Corp. He received his undergraduate degree from Santa Clara University.
Matthew E. Korenberg Founder of Neurocircuit Therapeutics, Inc., Matthew E. Korenberg presently is EVP, Chief Financial & Accounting Officer at Ligand Pharmaceuticals, Inc. In the past he occupied the position of Chief Executive Officer & Director at Neurocircuit Therapeutics, Inc. and Managing Director at Goldman Sachs & Co. LLC. Mr. Korenberg received an undergraduate degree from the University of Michigan.
Todd Pettingill Presently, Todd Pettingill holds the position of Investor Relations Contact at Ligand Pharmaceuticals, Inc.
Nancy Ryan Gray Nancy Ryan Gray is on the board of Ligand Pharmaceuticals, Inc. and President & Chief Executive Officer for Gordon Research Conferences and Member of American Chemical Society. In the past Dr. Gray occupied the position of Membership Director at American Chemical Society. Dr. Gray received a doctorate from The Pennsylvania State University and an undergraduate degree from the University of Notre Dame.
Eric Vajda Eric Vajda is Vice President-Preclinical Research & Development at Ligand Pharmaceuticals, Inc. Dr. Vajda received an undergraduate degree from Yale University and a doctorate from the University of Utah.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐